Cardiologist. Inherited Cardiovascular Diseases. Cardiopatías y Aortopatías Familiares. @HUnivValdecilla H.U. Marqués de Valdecilla. Santander. 🇪🇸

Joined January 2020
Luis Ruiz Guerrero retweeted
Cardiopulmonary exercise testing in contemporary cardiology: physiological insights, novel applications and evolving algorithms bit.ly/4c2zQIj
9
35
2,513
The proposed left atrium (LA) staging framework offers mechanistic insights into how the LA adapts to progressive diastolic dysfunction in #cvHCM. It is associated w/ a graded risk of NOAF and may help tailor AF surveillance strategies. Learn more: bit.ly/4yB0K2l #JACC
2
29
2
97
9,020
Luis Ruiz Guerrero retweeted
ACACIA-HCM trial topline results - aficamten in nHCM. Incredibly proud and thankful to our patients and team for their commitment and hard work. This represents the first effective treatment for patients with nHCM. looking forward to seeing the full results. #CardioTwitter
4
30
1
77
5,696
Luis Ruiz Guerrero retweeted
Danicamtiv enhanced cardiac myosin function in vitro and was generally well tolerated in #DCM. Echo findings suggest improved contractility, with strongest responses in #MYH7 and TTN cohorts jacc.org/doi/10.1016/j.jacc.… #JACC #cvDCM
1
9
1
40
5,243
Luis Ruiz Guerrero retweeted
Early-onset AF, especially without risk factors --> myocardial disease --> genetic evaluation medrxiv.org/content/10.1101/… #CardioTwitter
11
21
1,881
Luis Ruiz Guerrero retweeted
RBM20 cardiomyopathy carries a more significant burden at a younger age, and an accelerated course compared to TTN cardiomyopathy pmc.ncbi.nlm.nih.gov/article… #CardioTwitter
5
18
1,414
Luis Ruiz Guerrero retweeted
A deep dive into the mechanisms of ALPK3 associated HCM #CardioTwitter nature.com/articles/s41598-0…
1
7
17
1,656
📣New Consensus is out in #Europace #EHRA2025 💊The diagnostic role of pharmacological provocation testing in cardiac electrophysiology💥 🔗 doi.org/10.1093/europace/eua… @GiulioConte9 @Dominik_Linz @FraSantoroMD @AndyZhangMD @DavideMei93 @marcovitoloMD @LuigiDiBiaseMD
30
1
67
7,353
Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25. Check out the key findings ➡️ bit.ly/3DYGHEl
31
2
95
10,650
Luis Ruiz Guerrero retweeted
Late Gadolinium Enhancement in Early Repolarization Syndrome heartrhythmjournal.com/artic…
11
30
3,047
Luis Ruiz Guerrero retweeted
📅 The A Coruña Hypertrophic Cardiomyopathy Congress is Back! 🗓 September 18-19, 2025 🔬 Experts from 🇦🇷 🇦🇺 🇩🇪 🇪🇸 🇫🇷 🇬🇧 🇮🇹 🇳🇱 🇵🇹 🇺🇸 @seccCFyGenetCV @secardiologia 🔗 hypertrophiccardiomyopathyac…
1
21
1
42
4,205
Luis Ruiz Guerrero retweeted
Low penetrance sarcomere variants (LowSVs) contribute to mild HCM alone but increase severity with high-risk variants. @neallakdawala @drjamesware @tikuowens @jodieingles27 @S2beri @sday_hcm @SeanLZheng @AdamHelmsMD ahajournals.org/doi/abs/10.1…
1
16
1
34
8,843
Luis Ruiz Guerrero retweeted
🧬 24% of patients with heritable arrhythmias & cardiomyopathies carry a disease-causing variant—but only 8% see changes in clinical management. How do we close the gap? Read the study: jacc.org/doi/10.1016/j.jacc.… #JACC #Genetics #CardioScience #PrecisionMedicine #cvGenetics
32
71
9,913
Luis Ruiz Guerrero retweeted
Cardiopulmonary exercise testing (CPET) has a unique role in the assessment of cardiopulmonary disease. @BrazileTiffany and colleagues review key CPET variables, protocols and clinical indications. eviden.cc/4aC6uOt
1
108
4
283
45,751
Luis Ruiz Guerrero retweeted
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors. Learn more: nej.md/4h41K6k
90
3
250
29,393
Luis Ruiz Guerrero retweeted
🔬New in @JACCJournals: HCM diagnosis criteria show unexpected demographic bias. Study of 50,000+ hearts reveals current thresholds create 8:1 male-female ratio Proposing demographic-adjusted thresholds to improve diagnosis🫀 authors.elsevier.com/a/1kPE5… @UCL_ICS @NHSBartsHealth
5
27
2
58
6,884
Luis Ruiz Guerrero retweeted
This is nice work on an important question in EP. I have an idea about a subgroup. Mandrola theory of de novo AFlutter. If it occurs in pt w prior heart surgery, CTI likely enough. If no prior surgery, CTI + PVI better. #epeeps LOE 👆= opinion. #EPeeps
Should we isolate the pulmonary veins in all patients with atrial flutter? Does PVI replace the need for cavitricuspid isthmus isolation? Provocative findings in systematic led by Daniel Gomes. Great collaboration @SergeBoveda , @DhirajGuptaBHRS , et al. #Afib #atrialfibrillation
1
4
28
8,432
Luis Ruiz Guerrero retweeted
As promised, here is a slew of content ...re the PLATO trial of ticagrelor vs clopidogrel in patients with ACS This all occurred in 2009, early in my critical appraisal learning. Revisiting PLATO controversy is super important--both clinically and epistemologically
2
11
1
64
13,670